Short-term results of curcumin, quercetin, hyaluronic acid and chondroitin sulfate (Ialuril Soft Gels®) in the management of chronic prostatitis/primary prostate pain syndrome: a single-center prospective study
Clicks: 1
ID: 310101
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #364 of 490 articles by views in Frontiers in surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 490 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Aim of the studyManagement of Chronic Prostatitis/Primary Prostate Pain Syndrome (CP/PPPS) is challenging and characterized by conflicting results. This study aimed to evaluate the efficacy of a food supplement based on Curcumin, Quercetin, Hyaluronic Acid and Chondroitin Sulfate (Ialuril Soft Gels®) in CP/PPPS treatment.Materials and methodsData of consecutive male patients who referred to our Institution for CP/PPPS were prospectively collected between Oct-2022 and Jan-2023. Patients with maximum flow rate <15 ml/s, post-void residual >150 ml and/or previous prostate surgery were excluded. Variables including age, body mass index (BMI), prostate volume (PVol) and serum prostate specific antigen (PSA) were collected. Patients were asked to fulfil standardized questionnaires to assess severity of pain, lower urinary tract symptoms (LUTS) and erectile function, including Symptom Severity Index (SSI), Symptom Frequency Questionnaire (SFQ), National Institutes of Health Chronic Prostatitis Symptom Index (NHI/CPSI) (pain and LUTS domains), International Prostate Symptom Score (IPSS) and Quality of Life score (IPSS-QoL), and International Index of Erectile Function (IIEF-5). Changes in standardized questionnaires were evaluated at baseline, 30- and 90-days after enrolment. Patients were administered 2 gelcaps of Ialuril Soft Gels® (curcumin 200 mg, quercitin 200 mg, hyaluronic acid 100 mg, chondroitin sulfate 200 mg) once a day for 60 days.ResultsTwenty patients were analysed. Baseline features were age [median 50 years (IQR 46–51)], BMI [24.2 (22.8–28.3)], PVol [42 ml (30–52)], PSA [1.0 ng/ml (0.8–1.8)], SSI [54 (27–55)], SFQ [20 (13–26)], NHI/CPSI [pain domain 10 (8–13); LUTS domain 7 (4–8)], IPSS [13 (10–18)], IPSS-QoL [3 (2–3)] and IIEF-5 [17 (14–22)]. SSI and SFQ scores showed statistically significant differences both at 30- [SSI 45 (22–49), p < 0.001; SFQ 16 (11–20), p = 0.035] and 90-days [SSI 33 (17–42), p < 0.001; SFQ 13 (9–16), p < 0.001]. IPSS and NHI/CPSI pain and LUTS domains showed statistically significant differences at 30-days [IPSS 12 (10–13), p = 0.002; NHI/CPSI pain domain 6 (5–9), p < 0.001; NHI/CPSI LUTS domain 7 (2–9), p = 0.033, respectively], but not at 90-days (all p > 0.05). IPSS-QoL and IIEF-5 scores did not report any statistically significant difference during follow-up (p = 0.12 and p = 0.23, respectively). No adverse events were recorded.ConclusionsIaluril Soft Gels® seems to be effective in reducing the severity of pain and urinary symptoms in CP/PPPS patients at short-term follow-up.
| Reference Key |
imported_1768922111_696f9bff776a3
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Bove, Pierluigi |
| Journal | Frontiers in surgery |
| Year | 2025 |
| DOI |
10.3389/fsurg.2025.1700681
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.